DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for H syndrome — screening already-approved drugs against its 6-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleH syndrome maps to a 6-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for h syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
SMAD family member 4 (SMAD4) — SMAD4 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet pgedrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 9HZA · 2.03 Å · ligand TRIETHYLENE GLYCOL (PGE). Experimental structure, not a prediction.
What the evidence adds up to
A 2022 review of the literature on H syndrome treatment states that most treatment experiences are unsatisfactory, with the exception of hypertrichosis, which can be treated almost permanently by hair removal lasers. The review notes that earlier diagnosis and treatment may prevent short stature or other cutaneous or systemic complications, but provides no data from controlled trials to support this. Fewer than 120 cases of H syndrome have been reported worldwide as of 2020. The disease is caused by mutations in SLC29A3, the gene encoding equilibrative nucleoside transporter 3, and a 2015 report identified a novel homozygous insertion-deletion mutation (c. 1269_1270delinsA) in an 18-year-old Chinese patient.
The 2022 review searched Medline, Scopus, Web of Sciences, and Google Scholar for treatment methods and their effects on common symptoms, but does not name any drug therapy that produced satisfactory outcomes. A 2023 case report describes a 37-year-old woman referred to rheumatology with a prediagnosis of rheumatoid arthritis due to hand and foot deformity and sensorineural hearing loss since age 17, but no treatment for H syndrome is discussed in that report. A 2020 case report mentions low bone mineral density associated with hypovitaminosis D and low insulin-like growth factor 1 in an H syndrome patient, but does not report any intervention or its outcome.
No randomised trial, no prospective treatment study, and no drug with demonstrated efficacy in H syndrome is described in these abstracts. What is missing is any funded clinical trial, any validated outcome measure for the disease, and any stratification of patients by mutation type or symptom severity.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Family Medicine and Primary Care · 2022 · 16 citations · open access
Review of the current literature on H syndrome treatment
AbstractH syndrome is a systemic inherited autosomal recessive histiocytosis, with characteristic cutaneous findings accompanying systemic manifestations and a most common genetic mutation (OMIM 612391) as SLC29A3. The term "H Syndrome" is representative of presentation with hyperpigmentation, hypertrichosis, hepatosplenomegaly, heart anomalies, hearing loss, hypogonadism, low height, and, occasionally, hyperglycemia. H syndrome is new and growing entity in medicine. This syndrome is not specific to a region or a nationality. There are very few treatment experiences on H Syndrome patients and most of them are unsatisfactory apart from hypertrichosis, which is able to treat almost permanently by hair removal lasers. Latest findings suggest that there is possibility of prevention of short stature or other cutaneous or systemic complications in this syndrome with earlier diagnosis and treatment. We searched Medline, Scopus, Web of Sciences, and Google Scholar, up to now and reviewed previous published papers with emphasis on treatment methods and its effects on certain common symptoms.
Chinese Medical Journal · 2015 · 6 citations · open access
Identification of a Novel Mutation in Solute Carrier Family 29, Member 3 in a Chinese Patient with H Syndrome
AbstractBACKGROUND: H syndrome (OMIM 612391) is a recently described autosomal recessive genodermatosis characterized by indurated hyperpigmented and hypertrichotic skin, as well as other systemic manifestations. Most of the cases occurred in the Middle East areas or nearby countries such as Spain or India. The syndrome is caused by mutations in solute carrier family 29, member 3 (SLC29A3), the gene encoding equilibrative nucleoside transporter 3. The aim of this study was to identify pathogenic SLC29A3 mutations in a Chinese patient clinically diagnosed with H syndrome. METHODS: Peripheral blood samples were collected from the patient and his parents. Genomic DNA was isolated by the standard method. All six SLC29A3 exons and their flanking intronic sequences were polymerase chain reaction (PCR)-amplified and the PCR products were subjected to direct sequencing. RESULTS: The patient, an 18-year-old man born to a nonconsanguineous Chinese couple, had more extensive cutaneous lesions, involving both buttocks and knee. In his genomic DNA, we identified a novel homozygous insertion-deletion, c. 1269_1270delinsA, in SLC29A3. Both of his parents were carriers of the mutation. CONCLUSIONS: We have identified a pathogenic mutation in a Chinese patient with H syndrome.
JAAD Case Reports · 2020 · 3 citations · open access
H syndrome with low bone mineral density associated with hypovitaminosis D and low insulin-like growth factor 1
AbstractH syndrome is a rare autosomal recessive disorder that occurs because of mutations in the SLC29A3 gene, encoding the human equilibrative nucleoside transporter, which is a protein located in endosomes, lysosomes, and mitochondria.1-5 It was first named by Molho-Pessach et al in 2008.1 To date, fewer than 120 cases of this rare disease have been reported worldwide.5 It is characterized by the presence of hyperpigmented indurated patches with overlying hypertrichosis symmetrically involving the inner aspects of the thighs, which may extend to the posterior aspects of the lower limbs, abdomen, and back, while sparing the knees and buttocks.
The Journal of Rheumatology · 2023 · 0 citations · open access
Rheumatoid Arthritis or Imitator?
AbstractH syndrome is an autosomal recessive multisystemic disease with a very low prevalence rate, characterized by indurated cutaneous hyperpigmentation, hypertrichosis, and various systemic manifestations. A 37-year-old woman was referred to the rheumatology department with a prediagnosis of rheumatoid arthritis due to deformity in the hands and feet and mild sensorineural hearing loss since the age of 17.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
